GEMC- Cardiovascular Board Review Session 2- Resident Training
-
Upload
openmichigan -
Category
Education
-
view
879 -
download
1
description
Transcript of GEMC- Cardiovascular Board Review Session 2- Resident Training
![Page 1: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/1.jpg)
Project: Ghana Emergency Medicine Collaborative
Document Title: Cardiovascular Board Review for www.EMedHome.com
Part 2
Author(s): Joe Lex, MD (Temple University School of Medicine)
License: Unless otherwise noted, this material is made available under the
terms of the Creative Commons Attribution Share Alike-3.0 License:
http://creativecommons.org/licenses/by-sa/3.0/
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your
ability to use, share, and adapt it. These lectures have been modified in the process of making a publicly
shareable version. The citation key on the following slide provides information about how you may share and
adapt this material.
Copyright holders of content included in this material should contact [email protected] with any
questions, corrections, or clarification regarding the use of content.
For more information about how to cite these materials visit http://open.umich.edu/privacy-and-terms-use.
Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis
or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please
speak to your physician if you have questions about your medical condition.
Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
1
![Page 2: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/2.jpg)
Attribution Key
for more information see: http://open.umich.edu/wiki/AttributionPolicy
Use + Share + Adapt
Make Your Own Assessment
Creative Commons – Attribution License
Creative Commons – Attribution Share Alike License
Creative Commons – Attribution Noncommercial License
Creative Commons – Attribution Noncommercial Share Alike License
GNU – Free Documentation License
Creative Commons – Zero Waiver
Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in
your jurisdiction may differ
Public Domain – Expired: Works that are no longer protected due to an expired copyright term.
Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)
Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.
Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your
jurisdiction may differ
Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that
your use of the content is Fair.
To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
{ Content the copyright holder, author, or law permits you to use, share and adapt. }
{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }
{ Content Open.Michigan has used under a Fair Use determination. }
2
![Page 3: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/3.jpg)
Cardiovascular
Board Review for
www.EMedHome.com Joe Lex, MD, FACEP, MAAEM
Professor of Emergency Medicine
Department of Emergency Medicine
Temple University School of Medicine
Philadelphia, PA USA 3
![Page 4: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/4.jpg)
Part Two 5. Diseases of the Myocardium
Cardiac Failure
Cardiomyopathy
CHF
Coronary Syndromes
Myocardial Infarction
Myocarditis
Ventricular Aneurysm 4
![Page 5: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/5.jpg)
3.5 Acquired
Diseases of the
Myocardium
5 Patrick J. Lynch (Wikimedia Commons)
![Page 6: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/6.jpg)
3.5.1.1 Cor
Pulmonale
6
Mariana Ruiz (Wikipedia)
![Page 7: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/7.jpg)
Cor Pulmonale
Cor = heart
Pulmonale = of the lungs
In other words, pulmonary heart
disease
Also known as “right heart failure”
7
![Page 8: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/8.jpg)
Cor Pulmonale
Chronic: right ventricle
hypertrophy
Adaptive response to long-
term in pressure
Acute: right ventricle dilatation
Stretching of ventricle in
response to acute in
pressure 8
![Page 9: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/9.jpg)
Acute Cor Pulmonale
Massive pulmonary embolization
Exacerbation of chronic cor
pulmonale
9
![Page 10: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/10.jpg)
Chronic: Many Causes 1
COPD
Primary pulmonary hypertension
Asthma
Recurrent pulmonary embolism
Loss of lung tissue following
trauma or surgery
End stage pneumoconiosis
10
![Page 11: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/11.jpg)
Chronic: Many Causes 2
Sarcoidosis
T1-4 vertebral subluxation
Obstructive sleep apnea
Altitude sickness
Sickle cell anemia
Bronchopulmonary dysplasia (in
infants)
11
![Page 12: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/12.jpg)
Signs & Symptoms 1
Shortness of breath on exertion
At rest when severe
Wheezing
Chronic wet cough
Ascites
Pedal edema
Prominent neck and facial veins
12
![Page 13: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/13.jpg)
Signs & Symptoms 2
Hepatomegaly
Abnormal heart sounds
Bi-phasic atrial response on EKG
due to hypertrophy
13
![Page 14: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/14.jpg)
Chest X-Ray
Right ventricular hypertrophy
Right atrial dilatation
Prominent pulmonary artery
Peripheral lung fields: vascular
markings
Changes of COPD
14
![Page 15: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/15.jpg)
Chest X-Ray Right
ventricular
hypertrophy
Right atrial
dilatation
Prominent
pulmonary
artery
Peripheral
lung fields:
vascular
markings
(COPD) 15
Source Undetermined
![Page 16: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/16.jpg)
ECG RVH
Right axis deviation
Prominent R wave in lead V1
Inverted T waves in right precordial
leads
Large S in I, II and III
Large Q in lead III
Tall peaked P waves (P pulmonale)
in II, III and aVF 16
![Page 17: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/17.jpg)
ECG P pulmonale
Peaked P waves in inferior leads >2.5
mm (P pulmonale)
Absent R waves in right precordial
leads (SV1-SV2-SV3 pattern) 17
Source Undetermined Source Undetermined
![Page 18: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/18.jpg)
What We Need to Know 1
Sildenafil = Revatio® = Viagra®
PDE5 inhibitor
Relaxes arterial wall
pulmonary arterial resistance and
pressure workload of
right ventricle symptoms
Beware of using nitrates
refractory hypotension
18
![Page 19: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/19.jpg)
What We Need to Know 2
Epoprostenol = PGI2 = Flolan®
Delivered by pump: very short T½
Sudden cessation rebound
pulmonary hypertension
Dyspnea, dizziness, etc.
Potent platelet inhibitor major
bleed risk
19
![Page 20: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/20.jpg)
3.5.1.2 High Output
Cardiac Failure
20
![Page 21: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/21.jpg)
High Output Failure
Term is misnomer
Many conditions: heart is normal,
can generate cardiac output
Underlying problem: in systemic
vascular resistance threatens
arterial blood pressure activation
of neurohormones salt and
water retention by kidney
21
![Page 22: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/22.jpg)
High Output: Causes 1
Chronic severe anemia
Large AV fistula
22 Source Undetermined
![Page 23: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/23.jpg)
High Output: Causes 2
Multiple small arteriovenous shunts
e.g. Paget's disease of bone
Some severe hepatic or renal
disorders
Hyperthyroidism
Beriberi
23
![Page 24: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/24.jpg)
High Output: Causes 3
Acutely in septic shock, especially
Gram-negative bacteria
24 Source Undetermined
![Page 25: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/25.jpg)
High Output Failure
Many high output states are
curable conditions
Untreated leads to systolic failure
Since associated with peripheral
vascular resistance, use of
vasodilator therapy may aggravate
the problem
25
![Page 26: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/26.jpg)
3.5.1.3 Low Output
Cardiac Failure
26
![Page 27: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/27.jpg)
Low Output Cardiac Failure
cardiac output but normal
demand for blood
Manifestations of impaired
peripheral circulation and
vasoconstriction
Most forms of heart disease
Covered in Section 3.5.3:
Congestive Heart Failure
27
![Page 28: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/28.jpg)
3.5.2
Cardiomyopathy
28
![Page 29: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/29.jpg)
Cardiomyopathy
Literally “heart muscle disease”
Measurable deterioration of myocardial function
Usually leads to heart failure
Most common form: dilated
Common symptoms: dyspnea and peripheral edema
At risk for dysrhythmias, sudden cardiac death
29
![Page 30: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/30.jpg)
Extrinsic Causes
Primary pathology: outside
myocardium itself
Most cardiomyopathies are
extrinsic
Most common cause: ischemia
30
![Page 31: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/31.jpg)
Intrinsic Causes
Not due to identifiable external
cause
Causes can be found for most
31
![Page 32: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/32.jpg)
Signs & Symptoms
Can mimic virtually any form of
heart disease
Chest pain: common
Severe cases associated with heart
failure, arrhythmias, and systemic
embolization
32
![Page 33: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/33.jpg)
Dilated Cardiomyopathy
Ventricular dilatation and global
myocardial dysfunction (<40%)
Usually present with biventricular
failure, e.g. fatigue, dyspnea,
orthopnea, ankle edema
2-year survival = 50%
Progressive cardiogenic
shock or sudden cardiac
death 33
![Page 34: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/34.jpg)
Dilated Cardiomyopathy
Ischemic: following massive
anterior MI due to extensive
myocardial necrosis and loss of
contractility
Non-ischemic: most are idiopathic
ECG usually abnormal, but no
features unique to DCM
34
![Page 35: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/35.jpg)
Non-Ischemic Cardiomyopathy
HOCM
Restrictive
Dilated
Myocarditis
Tako-Tsubo
35
Source Undetermined
![Page 36: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/36.jpg)
Restrictive Cardiomyopathy
Least common
Occurs in advanced stages of
myocardial infiltrative disease
Hemochromatosis,
amyloidosis, sarcoidosis, etc.
Diffuse myocardial infiltration leads
to low voltage QRS complexes
No specific ECG findings 36
![Page 37: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/37.jpg)
Peripartum Cardiomyopathy
Symptoms and signs of heart
failure that present initially during
last 3 months of pregnancy or first 5
months postpartum
Clinically identical to dilated CM
Complain of chest pain, palpitations
May be in CHF: rales, dyspnea,
cardiomegaly, +S3
37
![Page 38: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/38.jpg)
Peripartum Cardiomyopathy
ECG left ventricular hypertrophy
NSST-T wave changes
Echocardiography: all 4 chambers
enlarged, left ventricular systolic
function
preload & afterload, contractility
If pregnant: hydralazine, labetalol
Mortality ~2% 38
![Page 39: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/39.jpg)
3.5.2.1 Hypertrophic
Cardiomyopathy
39
![Page 40: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/40.jpg)
Hypertrophic Cardiomyopathy
Leading cause of sudden cardiac
death in young athletes
Frequently asymptomatic until
sudden cardiac death
Prevalence 0.2 – 0.5% of general
population
40
![Page 41: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/41.jpg)
Mechanism
Asymmetric septal hypertrophy
(~2/3)
Aortic stenosis & HTN have
symmetric hypertrophy
Dynamic outflow obstruction
At rest ~25%
Can be provoked in ~70%
If obstruction HOCM 41
![Page 42: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/42.jpg)
Symptoms
Dyspnea most common
Chest pain
Palpitations
Lightheadedness
Fatigue
Syncope
Sudden cardiac death
42
![Page 43: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/43.jpg)
Findings: Murmur 1
Murmur similar to aortic stenosis
Classically, murmur is loudest at
left parasternal edge, 4th intercostal
space, rather than aortic area
43
![Page 44: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/44.jpg)
Findings: Murmur 2
HCM murmur in intensity with
any maneuver that volume of
blood in left ventricle
Stand abruptly
Valsalva
Amyl nitrite murmur by
venous return to heart
44
![Page 45: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/45.jpg)
ECG Findings
LVH precordial voltages, non-
specific ST / T-wave abnormalities
45 Source Undetermined
![Page 46: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/46.jpg)
ECG Findings
Asymmetric hypertrophy
“dagger Q-waves” infero-lateral
46
Source Undetermined
![Page 47: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/47.jpg)
Management
Beta-blockers & calcium channel
blockers: slow heart rate, improve
diastolic function
Amiodarone: reduces ventricular
dysrhythmias
47
![Page 48: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/48.jpg)
3.5.3 Congestive
Heart Failure
48
![Page 49: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/49.jpg)
Types of Failure
Systolic dysfunction: failure of
ventricular contractility
AHA / ACC: left ventricular
ejection fraction <40%
Diastolic dysfunction: failure of
diastolic ventricular relaxation
high filling pressures
1/3 – ½: some renal insufficiency
49
![Page 50: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/50.jpg)
Left-Sided Heart Failure
Left ventricle does not pump
enough blood backs up into
lungs, causing pulmonary edema
LV heart failure eventually causes
right-sided heart failure
50
![Page 51: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/51.jpg)
Left-Sided Heart Failure
rate of breathing tachypnea
work of breathing
Rales or crackles: initially in lung
bases fluid in alveoli (pulmonary
edema
Cyanosis: late, severe
51
![Page 52: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/52.jpg)
Left-Sided Heart Failure
Laterally displaced apex beat
Gallop rhythm: from blood flow
or intra-cardiac pressure
Murmur can be cause (e.g. aortic
stenosis) or result (e.g. mitral
regurgitation) of heart failure
52
![Page 53: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/53.jpg)
Extra Heart Sound
Occurs soon after the normal two
“lub-dub” heart sounds (S1 and S2)
Associated with heart failure
Occurs at beginning of diastole,
~0.12 to 0.18 seconds after S2
Mnemonic ken-TUC-ky, with “ky”
representing S3
53
![Page 54: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/54.jpg)
Right-Sided Heart Failure
54
![Page 55: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/55.jpg)
Right-Sided Heart Failure
Right ventricle does not pump
enough blood backs up into
body systemic edema
Nocturia common: leg fluid returns
to circulation when flat
If severe: ascites, hepatomegaly
Possible jaundice, coagulopathy
55
![Page 56: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/56.jpg)
Peripheral Edema & Anasarca
56 Source Undetermined Source Undetermined
![Page 57: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/57.jpg)
Right-Sided Heart Failure
Jugular venous pressure: marker of
fluid status
Can be accentuated by eliciting
hepatojugular reflux
If right ventricular pressure
parasternal heave
Signifies compensatory in
contraction strength
57
![Page 58: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/58.jpg)
Jugular Venous Distention
58 Source Undetermined
![Page 59: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/59.jpg)
Biventricular Failure
Left + right + pleural effusions
Dull to percussion + breath
sounds at bases
Pleural veins drain both into both
systemic and pulmonary venous
system
If unilateral: usually right sided
59
![Page 60: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/60.jpg)
Radiographic Findings
60
The radiological signs of heart failure:
• Fluid in lung fissures
• Kerley B lines
• Prominent upper lobe pulmonary arteries
• Fluid in the lung interstitium
• Large heart
• Pleural effusion
![Page 61: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/61.jpg)
Radiographic Findings
Cardiomegaly
large heart
61
Source Undetermined
![Page 62: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/62.jpg)
Radiographic Findings
Cephalization =
upper lobe
blood diversion
Occurs when
PAWP 12-18
mmHg
62 Source Undetermined
![Page 63: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/63.jpg)
Radiographic Findings
Kerley B lines:
short parallel
lines at lung
periphery
Interlobular
septa: usually
<1 cm
PAWP 18–25
MMHg 63
Source Undetermined
![Page 64: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/64.jpg)
Radiographic Findings
Bat wing =
central
interstitial
edema
PAWP >25
mmHg
64
Source Undetermined
![Page 65: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/65.jpg)
B-Natriuretic Peptide
From distended ventricles
>500 pg/mL: highly associated with
heart failure (LR = 8.1)
100-500 pg/mL: indeterminate (LR
= 1.8)
<100 pg/mL: highly unlikely (LR =
0.13)
65
![Page 66: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/66.jpg)
Acute Management 1
Immediate therapeutic goals
Improve respiratory gas exchange
Maintain adequate arterial
saturation
left ventricular diastolic pressure
Maintain adequate cardiac and
systemic perfusion
66
![Page 67: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/67.jpg)
Acute Management 2
Noninvasive positive pressure
ventilation (NIPPV)
Continuous (CPAP) or inspiratory /
expiratory (BiPAP)
Recruit collapsed alveoli
functional residual capacity
improve oxygenation
work of breathing 67
![Page 68: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/68.jpg)
Acute Management 3
Result: left ventricular preload
and afterload by intrathoracic
pressure
More rapid restoration of normal
vital signs and oxygenation
Fewer intubations
68
![Page 69: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/69.jpg)
Management: Nitroglycerin 1
Lower doses: venodilation
preload
Higher doses: arteriolar dilation
blood pressure
afterload
69
![Page 70: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/70.jpg)
Management: Nitroglycerin 2
Sublingual 400 mcg x 3
Total 1200 mcg in 10 minutes
Good bioavailability
Start IV 50 – 80 mcg/min
Can go to 200 – 300 mcg / min for
BP control
70
![Page 71: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/71.jpg)
Management: Loop Diuretic
Furosemide standard
In volume overload: plasma
volume, preload, pulmonary
congestion
Diuresis unnecessary in low
plasma volumes
71
![Page 72: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/72.jpg)
Management: Morphine
Controversial: central sympatholytic
that releases vasoactive histamine
causes peripheral vasodilation
72 Vaprotan (Wikimedia Commons)
![Page 73: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/73.jpg)
Management: ACE Inhibitor
Controversial: good afterload
Enalaprilat IV (0.625 – 1.25 mg)
Captopril sublingual (12.5 – 25 mg)
No good, large studies
Some sources say “theoretically
harmful”
73
![Page 74: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/74.jpg)
3.5.4 Coronary
Syndromes
74
![Page 75: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/75.jpg)
Acute Coronary Syndromes
Continuum or progression of
coronary artery disease from
myocardial ischemia to necrosis
Stable angina unstable angina
acute myocardial infarction
75
![Page 76: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/76.jpg)
Classic Presentations
76 J. Heuser (Wikipedia) J. Heuser (Wikipedia)
![Page 77: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/77.jpg)
3.5.5 Ischemic
Heart Disease
77
![Page 78: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/78.jpg)
Classic Presentations
Stable Angina
Transient, episodic chest
discomfort that is predictable and
reproducible
Familiar symptoms occur from a
characteristic stimulus
Improve with rest or sublingual
nitroglycerin within few minutes
78
![Page 79: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/79.jpg)
Classic Presentations
Unstable Angina
New onset
Occurs at rest or with frequency
Severely limiting
Lasts longer than a few minutes
Resistant to meds that previously
relieved the symptoms
79
![Page 80: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/80.jpg)
Classic Presentations
Acute Myocardial Infarction
Retrosternal chest discomfort
lasting > 15 minutes
Dyspnea, diaphoresis, light-
headedness, palpitations, nausea
and/or vomiting
Radiation to arms, shoulders, neck
probability of ischemia
80
![Page 81: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/81.jpg)
Atypical Presentations
More common in elderly
History of angina often absent
Epigastric discomfort / indigestion
or nausea and vomiting
Shortness of breath
Syncope or confusion
Fatigue, dizziness, or generalized
weakness 81
![Page 82: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/82.jpg)
Atypical Presentations
So-called “Silent MI” vague
~12.5% of all MIs
Worse prognosis than “classic”
Suspect in elderly, diabetics, those
with spinal cord injuries or disease,
alcoholics
82
![Page 83: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/83.jpg)
Risk Factors, Major
Cigarette smoking
Hypertension
Diabetes Mellitus
Hypercholesterol
Hypercoagulability
Family history of
CAD at < 55 in first
degree relative
Prior history of
CAD
PVD
Carotid
arteriosclerosis
83
![Page 84: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/84.jpg)
Risk Factors, Other
Male sex
Advanced age
Methamphetamine use
Cocaine use
Obesity
Inactive Lifestyle
Post-menopause
84
![Page 85: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/85.jpg)
Factors Predicting AMI
History ischemic heart disease
Chest pain / discomfort worse than
usual angina
Pain
similar to a prior AMI
lasts longer than an hour
radiates to jaw / neck / shoulder / arm
85
![Page 86: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/86.jpg)
Diagnosis
Normal initial EKG / troponin does
NOT rule out MI
History: most important tool
Suspect history: admit “ROMI”
Typically ≤ 25%of ROMI have
discharge diagnosis of “Acute MI”
Improvement after nitroglycerin /
antacid dose NOT rule in / out
86
![Page 87: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/87.jpg)
EKG
Most important adjunctive
diagnostic test
Initial EKG diagnostic in only ~25-
50%
Normal / non-diagnostic initial
EKG does not rule out ACS
87
![Page 88: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/88.jpg)
NSTEACS
Non-ST-elevation acute coronary
syndrome (NSTEACS)
Non-ST-elevation myocardial
infarction (NSTEMI)
Unstable angina (UA)
Differentiation may be retrospective
based on cardiac biomarkers
88
![Page 89: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/89.jpg)
NSTEACS
Non-ST-elevation acute coronary
syndrome (NSTEACS)
Main ECG abnormalities
ST segment depression
T wave flattening or inversion
89
![Page 90: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/90.jpg)
Causes of ST Depression
Myocardial
ischemia /
NSTEMI
Reciprocal
change in STEMI
Posterior MI
Digoxin effect
Supraventricular
tachycardia
Hypokalemia
RBBB
Right ventricular
hypertrophy
LBBB
Left ventricular
hypertrophy
Ventricular paced
rhythm 90
![Page 91: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/91.jpg)
Causes of T Wave Inversion
Normal in children
Persistent
juvenile T wave
pattern
Myocardial
ischemia /
infarction
Bundle branch
block
Ventricular
hypertrophy
(‘strain’ patterns)
Pulmonary
embolism
Hypertrophic
cardiomyopathy
intracranial
pressure
91
![Page 92: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/92.jpg)
Ischemic T Wave Inversions
Ischemia: contiguous leads based on
anatomical location of area of
ischemia / infarction:
Inferior = II, III, aVF
Lateral = I, aVL, V5-6
Anterior = V2-6
92
![Page 93: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/93.jpg)
Ischemic T Wave Inversions
Dynamic inversions with acute
myocardial ischemia
93
Source Undetermined
Source Undetermined
![Page 94: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/94.jpg)
Ischemic T Wave Inversions
Fixed inversions follow infarction, usually in association with pathological Q waves
94
Source Undetermined
Source Undetermined
![Page 95: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/95.jpg)
Biphasic T Waves
Two main causes:
Hypokalemia
Myocardial ischemia
Waves go in opposite directions:
Hypokalemic: go then
Ischemic: go then
95
![Page 96: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/96.jpg)
Biphasic T Waves
Due to hypokalemia: then
96
Source Undetermined
![Page 97: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/97.jpg)
Biphasic T Waves
Due to ischemia: then
97
Source Undetermined
![Page 98: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/98.jpg)
Biphasic T Waves: Wellens’
Inverted / biphasic T waves in V2-3
Patient presents with ischemic
chest pain
Highly specific for critical stenosis
of left anterior descending artery
98
![Page 99: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/99.jpg)
Biphasic T Waves: Wellens’
Type 1 Wellens’ T-waves: deeply
and symmetrically inverted
99
Source Undetermined
![Page 100: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/100.jpg)
Biphasic T Waves: Wellens’
Type 2 Wellens’ T-waves: biphasic,
with initial deflection positive and
the terminal deflection negative
100 Source Undetermined
![Page 101: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/101.jpg)
Flattened T Waves
Non-specific
Dynamic or in contiguous leads:
think ischemia
Generalized: think electrolyte
abnormality, like hypokalemia
101 Source Undetermined
![Page 102: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/102.jpg)
Inverted U Wave
Infrequently recognized but specific
sign of myocardial ischemia
102 Source Undetermined
![Page 103: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/103.jpg)
TIMI Risk Score 1
Thrombolysis In Myocardial Infarction
Assesses risk of death and
ischemic events in patients with
unstable angina or a non-ST
elevation myocardial infarction
103
![Page 104: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/104.jpg)
TIMI Risk Score 1
1. Age >= 65
2. ASA use in last 7 days
3. 2 angina episodes in last 24hrs
4. ST changes 0.5mm on admit EKG
5. serum cardiac biomarkers
6. Known CAD: stenosis 50%
7. 3 risk factors for CAD: cigarette
smoking, hypertension, HDL < 40,
diabetes, family history 104
![Page 105: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/105.jpg)
TIMI Risk Score
14 day risk: all-cause mortality, new or recurrent MI, or ischemia requiring urgent revascularization
0 or 1 = 4.7% risk
2 = 8.3% risk
3 = 13.2% risk
4 = 19.9% risk
5 = 26.2% risk
6 or 7 = 40.9% risk 105
![Page 106: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/106.jpg)
NSTEACS
50% of UA patients will show
evidence of myocardial necrosis
based on cardiac serum markers
such as troponin T or I and creatine
kinase isoenzyme (CK)-MB
Diagnosis of non-ST elevation
myocardial infarction
106
![Page 107: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/107.jpg)
NSTEACS: Treatment
Oxygen: evidence unclear
Nitroglycerin: vasodilate coronary
arteries, blood flow to heart
Antiplatelet agent: aspirin /
clopidogrel to reduce progression of
clot formation
Anticoagulant: heparin,
unfractionated or LMWH
107
![Page 108: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/108.jpg)
3.5.6 Myocardial
Infarction
108
![Page 109: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/109.jpg)
EKG for STEMI
amplitude R and T waves
(“giant” R / “hyperacute” T)
1st change to occur in evolving MI
Transient finding: may resolve by
presentation
109
Source Undetermined
![Page 110: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/110.jpg)
EKG for STEMI
amplitude R “giant” R waves
110 Source Undetermined
![Page 111: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/111.jpg)
EKG for STEMI
ST usually earliest recorded sign
± reciprocal changes
Initial up-sloping portion of ST
segment usually convex or flat
(horizontally or obliquely)
Q waves: represent myocardial
necrosis but not severity of infarct
Inverted T waves 111
![Page 112: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/112.jpg)
Other Causes of ST 1
Early repolarization
Acute pericarditis: all except aVR
Pulmonary embolism: V1 and aVR
Hypothermia: V3-V6, II, III and aVF
Hypertrophic cardiomyopathy: V3-5
Hyperkalemia: V1-V2 (V3)
112
![Page 113: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/113.jpg)
Other Causes of ST 2
Acute neurologic events: all leads,
primarily V1-V6
Acute sympathetic stress: all leads,
especially V1-V6
Brugada syndrome
Ventricular aneurysm
Cardiac contusion
113
![Page 114: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/114.jpg)
Other Causes of ST 3
Left ventricular hypertrophy
Idioventricular rhythm including
paced rhythm
114 Source Undetermined
![Page 115: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/115.jpg)
Early Repolarization 1
ST segment elevation without
underlying disease
Probably has nothing to do with
actual early repolarization
Commonly seen in young men
115
![Page 116: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/116.jpg)
Early Repolarization 2
Characteristics
Upward concave elevation of RS-T
segment with distinct or
“embryonic” J waves
Slurred downstroke of R waves or
distinct J points or both
RS-T segment elevation in
precordial leads
116
![Page 117: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/117.jpg)
Early Repolarization 3
Characteristics
Rapid QRS transition in precordial
leads with counterclockwise rotation
Persistence of these characteristics
for many years
Absent reciprocal ST depression
Large symmetrical T waves
117
![Page 118: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/118.jpg)
Early Repolarization 4
Generalized concave ST elevation in
precordial (V2-6) and limb leads (I, II,
III, aVF) 118
Source Undetermined
![Page 119: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/119.jpg)
Early Repolarization 5
J-point notching evident in inferior
leads (II, III and aVF)
119
Source Undetermined
![Page 120: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/120.jpg)
Early Repolarization 6
J-point notching evident in inferior
leads (II, III and aVF)
120
Source Undetermined
![Page 121: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/121.jpg)
Early Repolarization 7
Prominent, slightly asymmetrical T
waves that are concordant with main
vector of QRS complexes 121
Source Undetermined
![Page 122: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/122.jpg)
Early Repolarization 8
Descending limb of T wave is straighter
and slightly steeper than ascending
limb 122
Source Undetermined
![Page 123: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/123.jpg)
Early Repolarization 9
Descending limb of T wave is straighter
and slightly steeper than ascending
limb 123
Source Undetermined
![Page 124: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/124.jpg)
Specific
Infarcts
124
![Page 125: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/125.jpg)
125
Effects of Myocardial Ischemia,
Injury, and Infarction on the ECG
![Page 126: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/126.jpg)
126
Patrick J. Lynch (Wikipedia)
![Page 127: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/127.jpg)
Left Main Occlusion
Widespread horizontal ST
depression, most prominent in
leads I, II and V4-6
ST elevation in aVR ≥ 1mm
ST elevation in aVR ≥ V1
127
![Page 128: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/128.jpg)
Left Main Occlusion
Widespread ST depression, most
prominent in lateral leads (V4-6, I, aVL)
ST elevation > 1mm in aVR 128
Source Undetermined
![Page 129: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/129.jpg)
Left Main Occlusion
Widespread ST depression, most
prominent in lateral leads (V4-6, I, aVL)
ST elevation > 1mm in aVR 129
Source Undetermined
![Page 130: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/130.jpg)
Left Main Occlusion
Widespread ST depression, most
prominent in lateral leads (V4-6, I, aVL)
ST elevation > 1mm in aVR 130
Source Undetermined
![Page 131: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/131.jpg)
Left Main Occlusion
Widespread ST depression, most
prominent in lateral leads (V4-6, I, aVL)
ST elevation > 1mm in aVR 131
Source Undetermined
![Page 132: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/132.jpg)
132
Patrick J. Lynch (Wikipedia)
![Page 133: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/133.jpg)
Anterior STEMI
Occlusion of left anterior
descending artery (LAD)
Worst prognosis infarct size
ST segment with Q wave
formation in precordial leads (V1-6)
± high lateral leads (I and aVL)
Reciprocal ST in inferior leads
(mainly III and aVF)
133
![Page 134: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/134.jpg)
Anterior STEMI: Hyperacute
134
Source Undetermined
Source Undetermined
![Page 135: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/135.jpg)
Anterior STEMI: Acute
135
Source Undetermined
Source Undetermined
![Page 136: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/136.jpg)
Anterior STEMI: Acute
Q waves in V1-2
Reduced R wave height (Q-wave
equivalent) in V3-4
136
Source Undetermined
![Page 137: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/137.jpg)
Anterior STEMI: Tombstone
137 Source Undetermined
![Page 138: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/138.jpg)
Anterior STEMI: Tombstone
Proximal LAD large infarction with
poor LV ejection fraction
High likelihood of cardiogenic shock
and death 138
Source Undetermined
![Page 139: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/139.jpg)
STEMI: High Lateral
Occluded 1st diagonal branch (D1)
of LAD isolated ST in I, aVL
Occlusion of circumflex artery
ST in I, aVL, V5-6
139
![Page 140: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/140.jpg)
140
Patrick J. Lynch (Wikipedia)
![Page 141: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/141.jpg)
STEMI: High Lateral
ST elevation primarily localized to
leads I and aVL
Associated with reciprocal ST
depression and T wave inversion in
inferior leads
141
![Page 142: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/142.jpg)
STEMI: High Lateral
Occluded 1st diagonal branch (D1)
of LAD isolated ST in I, aVL
142
Source Undetermined
![Page 143: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/143.jpg)
STEMI: Lateral
Supplied by branches of LAD and
left circumflex (LCx) arteries
Usually as part of larger territory
infarction, e.g. anterolateral STEMI
Lateral extension of anterior,
inferior or posterior MI indicates
large territory of myocardium at risk
worse prognosis
143
![Page 144: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/144.jpg)
STEMI: Lateral
Isolated lateral STEMIs uncommon
Lateral STEMI as a stand-alone MI
is indication for emergent
reperfusion
144
![Page 145: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/145.jpg)
STEMI: Inferior 1
~80% dominant RCA
~18% dominant LCx
Rare: “type III” or wraparound LAD
concomitant inferior and anterior
ST elevation
145
![Page 146: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/146.jpg)
STEMI: Inferior 2
40-50% of all MIs
In general, more favorable
prognosis than AMI
~40% have concomitant right
ventricular infarction
Severe hypotension in
response to nitrates
Worse prognosis 146
![Page 147: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/147.jpg)
STEMI: Inferior 3
~20% develop significant
bradycardia due to 2o or 3o AV
block
in-hospital mortality (>20%)
May be associated with posterior
infarction
Worse prognosis due to area
of myocardium at risk
147
![Page 148: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/148.jpg)
STEMI: Inferior 4
ST in leads II, III and aVF
Progressive development of Q
waves in II, III and aVF
Reciprocal ST in aVL (± lead I)
148
![Page 149: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/149.jpg)
STEMI: Inferior 5
149
Source Undetermined
![Page 150: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/150.jpg)
150
Patrick J. Lynch (Wikipedia)
![Page 151: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/151.jpg)
STEMI: Inferior from RCA
ST in lead III > lead II
Reciprocal ST in lead I
Signs of right ventricular infarction
STE in V1 and V4R
151
![Page 152: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/152.jpg)
STEMI: Inferior from RCA
ST in lead III > lead II
Reciprocal ST and T wave
inversion in aVL
152
Source Undetermined
![Page 153: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/153.jpg)
STEMI: Inferior from RCA
ST in lead III > lead II
Reciprocal ST and T wave
inversion in aVL
153 Source Undetermined
![Page 154: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/154.jpg)
154
Patrick J. Lynch (Wikipedia)
![Page 155: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/155.jpg)
STEMI: Inferior from LCx
ST in lead II = lead II
Reciprocal ST and T wave
inversion in I or aVL
Q wave in III, aVF
155 Source Undetermined
![Page 156: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/156.jpg)
Right Ventricular Infarct
Isolated RV infarct rare
Complicates ~40% of inferior
STEMIs
Poor RV contractility preload
sensitive
Nitrates severe hypotension
Treat with fluid loading
156
![Page 157: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/157.jpg)
Right Ventricular Infarct
ST in V1
Only standard ECG lead that
looks directly at the right ventricle
ST in lead III > lead II
Lead III more “rightward
facing” than lead II
Must do right-sided leads
157
![Page 158: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/158.jpg)
Right Ventricular Infarct
158
V1R V2R
V3R
V4R V5R
V6R
Arcadian (Wikimedia Commons)
![Page 159: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/159.jpg)
Right Ventricular Infarct
ST in V1
ST in lead III > lead II
159 Source Undetermined
![Page 160: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/160.jpg)
Right Ventricular Infarct
Right-sided leads
ST in lead III > lead II
ST throughout right-sided leads
V3R-V6R
160 Source Undetermined
![Page 161: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/161.jpg)
Posterior Infarct
Accompanies 15-20% of STEMIs,
usually inferior or lateral
Isolated posterior MI (3-11%)
Lack of obvious ST means
diagnosis often missed
Isolated posterior infarct is
indication for emergent
coronary reperfusion
161
![Page 162: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/162.jpg)
Posterior Infarct
Suggested by changes in V1-3
Leads look at internal surface of
posterior myocardium
Horizontal ST depression
Tall, broad R waves (>30ms)
Upright T waves
Dominant R wave (R/S ratio > 1) in
V2 162
![Page 163: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/163.jpg)
Posterior Infarct
ST becomes ST
Q waves become R waves
Terminal T-wave inversion
becomes an upright T wave
163 Source Undetermined
![Page 164: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/164.jpg)
Posterior Infarct
Same EKG flipped upside down
Now looks like typical STEMI
Also with posterior leads
164 Source Undetermined
![Page 165: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/165.jpg)
Posterior Infarct
Same EKG flipped upside down
Now looks like typical STEMI
Also with posterior leads
165
Source Undetermined
![Page 166: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/166.jpg)
Posterior Infarct: Leads
166
Scapula
V7 V8 V9
Source Undetermined
![Page 167: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/167.jpg)
Posterior Infarct
Posterior extension of inferior or
lateral infarct implies much larger
area of myocardial damage
risk of left ventricular dysfunction
and death
167
![Page 168: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/168.jpg)
Posterior Infarct
Tall, broad R waves (>30ms)
Upright T waves
Dominant R wave (R/S ratio>1) in
V2
168
Source Undetermined Source Undetermined
![Page 169: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/169.jpg)
Posterior
Tall, broad
R waves
(>30ms)
Upright T
waves
Dominant R
wave (R/S
ratio>1) V2
169 Source Undetermined
![Page 170: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/170.jpg)
Posterior Infarct
Same patient, posterior leads V7 –
V9
170
Source Undetermined
![Page 171: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/171.jpg)
Posterior Infarct
171
Source Undetermined Source Undetermined
![Page 172: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/172.jpg)
Q-Waves: Normal
Depolarization of interventricular
septum (“septal Qs”)
Lateral leads I, aVL, V5 and V6
172
![Page 173: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/173.jpg)
Q-Waves: Pathologic
Electrical signal passes through
stunned or scarred myocardium
Deflection amplitude of 25% or
more of subsequent R wave
>0.04 s (40 ms) wide, >2 mm
amplitude
173
![Page 174: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/174.jpg)
Q-Waves: Pathologic
Deflection amplitude of 25% or
more of subsequent R wave
>0.04 s (40 ms) wide, >2 mm
amplitude
174 Source Undetermined
![Page 175: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/175.jpg)
Initial EKG Useful for…
… screening
… risk stratification
… establishing criteria that
determine which therapeutic
interventions will be employed
175
![Page 176: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/176.jpg)
Serial EKGs
Nondiagnostic EKG but concern for
possible ongoing ischemia
Capture ischemic changes
Demonstrate stability
Detect silent ischemia
ST segment trend-monitoring
MAY improve detection
176
![Page 177: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/177.jpg)
Serum Biomarkers
177
Source Undetermined
![Page 178: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/178.jpg)
Serum Biomarkers
Proteins that leak from injured
myocardial cells through damaged
cell membranes into bloodstream
Troponin T / I
CK-MB
Obsolete: serum glutamic
oxaloacetic transaminase (SGOT)
/ lactate dehydrogenase (LDH)
178
![Page 179: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/179.jpg)
Serum Biomarkers: Troponin
179
Ayacop (Wikimedia Commons)
![Page 180: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/180.jpg)
Serum Biomarkers: Troponin
Marker for all heart damage, not
just AMI
Tachycardia, CHF, myocarditis,
pericarditis, defibrillation, contusion
in ~40% of patients with critical
illnesses such as sepsis
Severe GI bleed: mismatch
between myocardial oxygen
demand and supply 180
![Page 181: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/181.jpg)
Serum Biomarkers: Troponin
Type I MI: coronary artery
occlusion
Type II MI: low flow state leading
to troponin leakage
DIFFERENT PATHOLOGIES
DIFFERENT TREATMENTS
NOT ALWAYS OBVIOUS
181
![Page 182: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/182.jpg)
Serum Biomarkers: Troponin
Marker Rise
(hrs)
Peak
(hrs)
Remains
Elevated
Troponin T 6 12 – 18 10 – 14 days
Troponin I 6 12 – 18 7 – 10 days
CK-MB 4 – 10 20 <2 days
Myoglobin 2 – 3 4 – 24 <1 day
182
![Page 183: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/183.jpg)
Serum Biomarkers: Others
CK-MB: serum levels of two
variants of enzyme phospho-
creatine kinase
Isoenzymes CKM and CKB
Myoglobin: primary oxygen-
carrying pigment of muscle tissues
Very nonspecific for cardiac
damage 183
![Page 184: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/184.jpg)
Serum Biomarkers: Others
Marker Rise
(hrs)
Peak
(hrs)
Remains
Elevated
Troponin T 6 12 – 18 10 – 14 days
Troponin I 6 12 – 18 7 – 10 days
CK-MB 4 – 10 20 <2 days
Myoglobin 2 – 3 4 – 24 <1 day
184
![Page 185: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/185.jpg)
Use of Serum Markers
Admit / discharge decisions based
primarily on history and clinical
presentation
Marker detection requires sufficient
myocardial cell damage AND
enough time for markers to be
released into serum
185
![Page 186: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/186.jpg)
Use of Serum Markers
Initial markers have low sensitivity
for detecting ischemia, cannot be
used to reliably diagnose or exclude
ACS
No single determination of one
serum biomarker reliably identifies
or excludes AMI within <6 hrs of
symptom onset
186
![Page 187: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/187.jpg)
Use of Serum Markers
This is a moving target
High sensitivity troponins MAY
change everything (or may not)
Should we call them “Low
Specificity Troponins” instead?
Hot topic over next few years, but
will not be tested
187
![Page 188: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/188.jpg)
Diagnosing MI: WHO – 2000
Myocardial cell death
Markers of myocardial cell death
recovered from blood samples
Evidence of myocardial ischemia (ST-
T segment changes)
Loss of electrically functioning cardiac
tissue (Q waves)
Reduction / loss of tissue perfusion
Cardiac wall motion abnormalities
Pathology
Biochemistry
EKG
Imaging
188
![Page 189: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/189.jpg)
Two-Dimensional Echo
Detects regional wall motion
abnormalities that occur with AMI
Abnormality starts on 1st beat
Cannot distinguish ischemia, acute
infarction and old infarction
Operator-dependent
Not readily available
189
![Page 190: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/190.jpg)
Coronary Artery CT
Very controversial
A work in progress
Zealots on both sides
Something MAY emerge in next
few years
190
![Page 191: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/191.jpg)
Radionuclide Scanning
191
![Page 192: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/192.jpg)
Technetium (99mTc) sestamibi
Tracer taken up by myocardium in
proportion to blood flow
Bound to six methoxy-isobutyl-
isonitrile (MIBI) ligands
Detects perfusion defects and
hypokinesia
192
![Page 193: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/193.jpg)
Technetium (99mTc) sestamibi
Active chest pain + nondiagnostic
EKG 100% sensitive / 83-92%
specific
Pain-free patient: 65% sensitive
193
![Page 194: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/194.jpg)
Thallium 201 scintigraphy
194
Source Undetermined
![Page 195: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/195.jpg)
Thallium 201 scintigraphy
Reversibly taken up by normally
perfused cells
Areas of uptake indicate regions
of severe ischemia or infarction
≤6hrs of infarct 100% sensitive,
80% specific for AMI
Cannot distinguish new from old
195
![Page 196: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/196.jpg)
Stress Testing
Recommended by American
College of Cardiology and
American Heart Association
Treadmill test: sensitivity 73-90%,
specificity 50-74% (Modified Bruce
Protocol)
Nuclear test: sensitivity 81%,
specificity 85-95%
196
![Page 197: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/197.jpg)
Chest Pain Evaluation Unit
Safe, effective alternative to routine
admission for low-intermediate risk
patients with chest pain
Protocols vary but usually involve
serial studies (EKGs, markers) and
selective stress testing for
evaluation of risk stratification
197
![Page 198: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/198.jpg)
Treatment
198
![Page 199: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/199.jpg)
Treatment
IV (NS)
cardiac monitor
pulse
oximeter
Oxygen
Antiplatelet
agents
Anticoagulant
therapy
Nitroglycerin
Morphine
Beta-blocker
Reperfusion
therapy
ACE-I 199
![Page 200: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/200.jpg)
Treatment
IV (NS)
cardiac
monitor
pulse oximeter
Oxygen
Antiplatelet
agents
Anticoagulant
therapy
Nitroglycerin
Morphine
Beta-blocker
Reperfusion
therapy
ACE-I 200
![Page 201: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/201.jpg)
IV / Monitor / Pulse oximetry
201
![Page 202: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/202.jpg)
Treatment
IV (NS)
cardiac monitor
pulse
oximeter
Oxygen
Antiplatelet
agents
Anticoagulant
therapy
Nitroglycerin
Morphine
Beta-blocker
Reperfusion
therapy
ACE-I 202
![Page 203: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/203.jpg)
Oxygen
Low flow (2-4L) by nasal cannula
High flow associated with
mortality and infarct size
203
![Page 204: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/204.jpg)
Treatment
IV (NS)
cardiac monitor
pulse
oximeter
Oxygen
Antiplatelet
agents
Anticoagulant
therapy
Nitroglycerin
Morphine
Beta-blocker
Reperfusion
therapy
ACE-I 204
![Page 205: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/205.jpg)
Antiplatelet Agents: Aspirin
Irreversibly acetylates platelet
cyclo-oxygenase,
Rapid onset: within 60 minutes
205
![Page 206: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/206.jpg)
Antiplatelet Agents: Aspirin
325mg on arrival unless
contraindicated
Chew to maximize bioavailability
mortality, infarct size, and rate of
reinfarction
Maximal benefit if given within 4
hours of chest pain onset
NNT to save one life = 40 206
![Page 207: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/207.jpg)
Antiplatelet Agents: ADP
Clopidogrel / prasugrel / ticagrelor
platelet aggregation by inhibiting
ADP platelet activation
Second-line therapy for patients
who cannot take ASA
Less effective than ASA due to
delayed onset
207
![Page 208: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/208.jpg)
Antiplatelet Agents: ADP
Clopidogrel
Onset 2 – 3 hours
Can speed up by forced doses
Safety profile: similar to ASA
risk of CV events in patients with
UA or NSTEMI AND early
noninvasive approach is planned
208
![Page 209: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/209.jpg)
Clopidogrel & CABG
Clopidogrel treatment 7 days
before CABG: major bleeding
Prasugrel: even more bleeding
Ticagrelor: less bleeding
Urgent CABG likely within 7 days:
argument for omitting
thienopyridines during initial
management of ACS
209
![Page 210: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/210.jpg)
Clopidogrel & CABG
Clopidogrel / prasugrel / ticagrelor
are all ADP receptor antagonists
A stands for “adenosine”
What happens when we give our
patients adenosine for SVT?
210
![Page 211: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/211.jpg)
Clopidogrel & CABG
ST 1 mm in aVR: strong
predictor severe LMCA / 3VD
requiring CABG
Discuss with interventionalist /
thoracic surgeon use of clopidogrel
ST <1mm in aVR: negligible risk
severe LMCA / 3VD requiring
CABG
Thienopyridine can be safely given 211
![Page 212: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/212.jpg)
Antiplatelet Agents: G2B3A
Abciximab / eptifibatide / tirofiban
Glycoprotein (GP) IIb/IIIa receptor
antagonists
Block final common pathway for
platelet aggregation
Indications: prior to PCI
Discuss with interventional
cardiologist 212
![Page 213: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/213.jpg)
Treatment
IV (NS)
cardiac monitor
pulse
oximeter
Oxygen
Antiplatelet
agents
Anticoagulant
therapy
Nitroglycerin
Morphine
Beta-blocker
Reperfusion
therapy
ACE-I 213
![Page 214: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/214.jpg)
Anticoagulant Therapy
Unfractionated heparin
Low molecular weight heparin
Direct thrombin inhibitors
214
![Page 215: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/215.jpg)
Anticoagulant Therapy
Unfractionated heparin and
enoxaparin result in similar
outcomes at one year post MI
215
Melissa Wiese (Wikimedia Commons)
![Page 216: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/216.jpg)
Heparin
Heparin + ASA more effective than
either alone
Indicated in high risk patients with
ACS (AMI/UA)
incidence of DVT, reinfarction,
nonhemorrhagic CVA, and
formation / embolization of LV
thrombus in AMI
216
![Page 217: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/217.jpg)
Unfractionated Heparin
May be useful in unstable angina
by rate of subsequent transmural
infarction
Preferred by cardiologists taking
patients to cath lab because can be
turned off
217
![Page 218: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/218.jpg)
Unfractionated Heparin
No reperfusion: bolus 50 – 70
U/kg to maximum of 5000 U, then
IV drip 12 U/kg per hour
Fibrinolysis: bolus 60 – 100 U/kg to
maximum of 4000 U, then IV drip
12 U/kg per hour
PCI: bolus 50 – 70 U/kg to
maximum of 5000 U
218
![Page 219: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/219.jpg)
Low Molecular Weight Heparin
Acceptable in patients <75 years
without significant renal dysfunction
recurrent angina, AMI, need for
urgent revascularization, mortality
rate
Preferred agent in absence of renal
failure or planned CABG within 24
hours
219
![Page 220: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/220.jpg)
Low Molecular Weight Heparin
bleeding than unfractionated
heparin with equivalent or better
antithrombotic effects
Simple administration and dosing
Limited blood monitoring
More predictable anticoagulation
effect
220
![Page 221: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/221.jpg)
Low Molecular Weight Heparin
No reperfusion: no load,
1 mg/kg every 12 hours
Fibrinolysis: loading dose 30 mg IV
bolus, then 1 mg/kg subcutaneously
every 12 hours
PCI: unfractionated preferred
221
![Page 222: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/222.jpg)
Nitroglycerin (NTG) 1
Dilates collateral coronary vessels
collateral blood flow to ischemic
myocardium
Has antiplatelet effects
222
![Page 223: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/223.jpg)
Nitroglycerin (NTG) 2
infarct size and mortality
myocardial oxygen demand
preload
LV end-diastolic volume
afterload
May myocardial susceptibility to
ventricular dysrhythmias during
ischemia and reperfusion 223
![Page 224: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/224.jpg)
Nitroglycerin (NTG) 3
pain and consequently
catecholamine release
224
![Page 225: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/225.jpg)
Nitroglycerin (NTG) 4
For chest pain if systolic BP
>90mm Hg
Start with sublingual 0.4mg (400
mcg) q3 – 5 minutes prn pain
1200 mcg in 6 – 10 minutes
Excellent bioavailability (>80%)
Ointment / paste: pretty useless
225
![Page 226: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/226.jpg)
Nitroglycerin (NTG) 5
Intravenous: books say start @ 10
– 20 mcg/min and increase by 5 –
10 mcg/min until pain controlled or
SBP by 10%
In real life, start higher
Sublingual: 1200 mcg / 10 min =
120 mcg / min
226
![Page 227: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/227.jpg)
Nitroglycerin: Adverse
Hypotension: usually responds to
fluid bolus and leg elevation
Reflex tachycardia: can be
moderated by concomitant use of
beta-blocking agent
Contraindicated in patients taking
PDE5 inhibitors (e.g. sildenafil)
Avoid for 12–24 hours after using
227
![Page 228: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/228.jpg)
Beta Blockers (BB)
Potential benefits 1
oxygen demand: heart rate,
blood pressure, contractility
risk of ventricular fibrillation
automaticity, electro-
physiologic threshold for activation,
slowing conduction
228
![Page 229: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/229.jpg)
Beta Blockers (BB)
Potential benefits 2
Bradycardia prolongs diastole
coronary diastolic perfusion
remodeling, improves left
ventricular hemodynamic function
left ventricular diastolic function
with a less restrictive filling pattern
229
![Page 230: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/230.jpg)
Beta Blockers (BB)
Prefibrinolysis era: mortality benefit
10 – 15% in patients treated with
propranolol, metoprolol, atenolol
Early IV therapy associated with
reduction in infarct size
Reperfusion era: ~40% reduction in
mortality in both STEMI (Q wave) or
non-ST elevation (non-Q wave) MI
230
![Page 231: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/231.jpg)
Beta Blockers (BB)
Contraindications
HR <60/min
SBP
<100mmHg
Moderate to
severe LV
dysfunction
Hypoperfusion
Precipitated by
cocaine
PR interval
>0.24 sec
2o or 3o AV
block
Active
bronchospasm
231
![Page 232: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/232.jpg)
Morphine
Chest pain despite adequate
treatment with antiplatelet,
anticoagulant, anti-ischemics
pain and anxiety circulating
catecholamines tendency
toward dysrhythmias
both pre and afterload
myocardial oxygen demand
232
![Page 233: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/233.jpg)
Morphine
Adverse Effects
Hypotension / bradycardia
responds to fluid bolus and atropine
Respiratory depression
233
![Page 234: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/234.jpg)
Reperfusion Therapy
Thrombolytic (fibrinolytic) therapy
Percutaneous Coronary
Intervention (PCI)
234
![Page 235: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/235.jpg)
Fibrinolytic
Streptokinase (SK)
Anisoylated Plasminogen
Streptokinase Activator Complex
(APSAC, Eminase, Anisterplase)
Tissue Plasminogen Activator
(TPA, Activase, Alteplase)
Reteplase (RPA, Retavase)
Tenecteplase (TNK) 235
![Page 236: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/236.jpg)
Fibrinolytic
Converts plasminogen to plasmin
lyses fibrin content of acute
intracoronary thrombosis
reperfusion of coronary arteries
infarction size, residual LV
function, survival
236
![Page 237: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/237.jpg)
Fibrinolytic
Shorter time between symptom
onset and administration greater
reduction in mortality
Initiate ideally within 30 minutes of
ED arrival
237
![Page 238: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/238.jpg)
Criteria for Thrombolysis
Class I: treatment benefit established
ST > 0.1mV in two or more
contiguous leads
Time to therapy ≤ 12 hours
Age <75 years
Bundle branch block (old)
obscuring ST segment analysis but
history suggesting AMI 238
![Page 239: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/239.jpg)
Criteria for Thrombolysis
Class IIa: treatment likely to benefit
ST elevation
Age >75 years
239
![Page 240: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/240.jpg)
Criteria for Thrombolysis
Class IIb: treatment may benefit
ST elevation
Time to therapy >12-24 hours
SBP >180 or DBP >110
240
![Page 241: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/241.jpg)
Criteria for Thrombolysis
Class III: not indicated, may be
harmful
ST elevation, time to therapy >24
hours, Ischemic pain resolved
ST depression only
No ST elevation
True posterior MI
Presumed new BBB 241
![Page 242: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/242.jpg)
Absolute Contraindications
Any prior cerebral hemorrhage
Known structural CNS lesion
Ischemic stroke within 3 months
(unless TIA < 3 hrs)
Significant closed head / facial
injury within 3 months
Suspicion of aortic dissection
Active bleeding / bleeding disorder 242
![Page 243: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/243.jpg)
Relative Contraindications 1
Chronic, severe, poorly controlled HTN or severe HTN on admission (SBP > 180 or DBP > 119)
Traumatic / prolonged (>10min) CPR
Non-compressible vascular punctures
Major surgery or internal bleeding within 3-4 weeks
243
![Page 244: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/244.jpg)
Relative Contraindications 2
Any other CNS disease – structural
or functional – not noted above
Pregnancy
Active peptic ulcer
Current use of anticoagulants
Prior exposure / allergic reaction to
SK or anistreplase if using these
agents 244
![Page 245: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/245.jpg)
Complications
Systemic bleeding 2 – 10%
Cerebral hemorrhage < 1%
Hypotension 3 – 10%
Allergic phenomena 1.5 – 2%
Usually minor; most common with SK
Reperfusion dysrhythmias ~50%
PVCs, idioventricular rhythms
Failure to open occlusion ~20% 245
![Page 246: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/246.jpg)
Percutaneous Coronary Intervention
Angioplasty or stent placement
2000 AHA guidelines
Class I for patients <75 years
with ACS and signs of
cardiogenic shock
Class IIa for patients >75
years
246
![Page 247: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/247.jpg)
Percutaneous Coronary Intervention
Benefits
More effective than thrombolysis in
opening occluded arteries
Treats underlying fixed obstructed
coronary artery lesions as well as
relieve the acute thrombosis
Associated with lower incidence of
recurrent ischemia, reinfarction,
intracranial hemorrhage, and death 247
![Page 248: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/248.jpg)
Percutaneous Coronary Intervention
Cons
Needs to be implemented 60 – 90
minutes
Not all facilities have PCI available
on 24 hour basis
Performance varies based on
center’s volume and operator’s
experience
248
![Page 249: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/249.jpg)
Angiotensin Converting Enzyme Inhibitors
When administered within first 24
hours, incidence of severe
ventricular dysfunction and death
All with AMI should receive ACE-I
Not until 6 hours after initial therapy
has started, patient stable
Too early hypotension
249
![Page 250: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/250.jpg)
Angiotensin Converting Enzyme Inhibitors
Captopril 12.5mg PO BID
Lisinopril 5 mg PO qd
Contraindications
ACE-I allergy
Killip Class III or IV heart failure
Hypotension (SBP < 100)
Creatinine > 2.5
Renal artery stenosis
250
![Page 251: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/251.jpg)
Complications of AMI
251
![Page 252: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/252.jpg)
Dysrhythmias
Prehospital phase associated with
highest incidence lethal dysrhythmia
Ventricular fibrillation greatest in 1st
hour of infarction
252
![Page 253: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/253.jpg)
Dysrhythmias: Treatment 1
Treat if exacerbates myocardial
ischemia or could potentially
deteriorate into cardiac arrest
Consider treatment of PVCs if
Frequent (>30 / hour)
Multifocal
Short runs of ventricular tachycardia
Couplets / display R on T
phenomenon 253
![Page 254: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/254.jpg)
Dysrhythmias: Treatment 2
Initial treatment: optimally manage
underlying ischemia / infarction
Lidocaine vs procainamide vs
amioadarone: your call
254
![Page 255: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/255.jpg)
Heart Failure
Left ventricular failure: congestive
heart failure pulmonary edema
cardiogenic shock
Left ventricle impaired ≥25%
CHF / pulmonary edema
Left ventricle impaired ≥40%
cardiogenic shock
255
![Page 256: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/256.jpg)
Conduction Disturbances
AV Blocks: 1o and Mobitz I 2o
Generally due to vagal tone
Rarely progress to complete block
Usually associated with inferior MI
Generally respond to drug therapy:
atropine
256
![Page 257: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/257.jpg)
Conduction Disturbances
AV Blocks: Mobitz II 2o
Generally due to destruction of
infranodal conduction tissue
Sudden progression to complete
AV block may occur
Usually associated with anterior MI
Pacemaker indicated
257
![Page 258: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/258.jpg)
Conduction Disturbances
Bundle Branch Block
Identifies patients more likely to
develop CHF, AV block, V-Fib
Acute anterior wall MI + new
RBBB high risk of developing
complete AV block and / or
cardiogenic shock
258
![Page 259: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/259.jpg)
Some Other Complications
Cardiac rupture
Ventricular septal rupture
Papillary muscle dysfunction /
rupture
Mitral regurgitation
LV aneurysm
Thromboembolism
Pericarditis 259
![Page 260: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/260.jpg)
3.5.7 Myocarditis
260
![Page 261: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/261.jpg)
Myocarditis
Detected in ~10% of routine
autopsies
Numerous virus (especially
enterovirus), bacteria, fungi
South America: Chaga’s disease
Necrosis and destruction of cardiac
tissues
261
![Page 262: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/262.jpg)
Myocarditis
Complaints nonspecific: fever,
fatigue, myalgias, N/V/D
No sign or symptom sensitive or
specific
Unexplained tachycardia common,
but nonspecific
Cardiac exam often unremarkable
262
![Page 263: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/263.jpg)
Myocarditis
EKG findings nonspecific: sinus
tachycardia, low electrical activity
May be prolonged corrected Q-T
interval, AV block, acute MI pattern
Cardiac troponin usually
WBC / ESR / CRP: nonspecific
263
![Page 264: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/264.jpg)
Differential Diagnosis
Can masquerade as acute MI:
severe chest pain, ECG changes,
cardiac markers, heart failure
Patients with myocarditis usually
young, few risk factors for CAD
ECG abnormalities may extend
beyond distribution of single
coronary artery
264
![Page 265: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/265.jpg)
Treatment
Determined by patient's clinical
presentation and severity of
disease
Extends from limitation of activity to
rhythm and CHF treatment, ECMO,
VADs, and eventual cardiac
transplantation
265
![Page 266: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/266.jpg)
Chaga’s Disease
Common in Central America
Protozoan Trypanosoma cruzi with
transmission by insect vector
~75% have no cardiac symptoms
Syncope / presyncope in 2/3 who
are seropositive
Antitrypanosomal drugs:
benznidazole and nifurtimox 266
![Page 267: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/267.jpg)
Trichinosis
Ingestion of cysts of Trichinella
spiralis in undercooked meat, now
mostly game meats
Myocardial involvement in ~20% of
diagnosed cases, appears 2nd – 3rd
week of illness
Many cardiac and EKG findings
Corticosteroids + anti-helminthic
267
![Page 268: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/268.jpg)
Lyme Disease
Spirochete Borrelia burgdorferi
Carditis ~21 days after onset of
erythema migrans
Cardiac complications 4 - 10%
Conduction disturbances; BBB, 1st,
2nd, and 3rd degree heart block;
cardiac arrest; dysrhythmias; left
ventricular dysfunction
268
![Page 269: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/269.jpg)
Lyme Disease Treatment
Atropine or isoproterenol to treat
stable heart blocks
Temporary pacemaker often
required in unstable patients
IV penicillin or oral tetracycline can
reverse AV blocks
Erythromycin in kids
Ceftriaxone also effective 269
![Page 270: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/270.jpg)
Pharmacologic Causes
In addition to ischemia, cocaine
can cause myocarditis & dilated
cardiomyopathy
Doxorubicin can cause
pericarditis, dysrhythmias,
myocarditis, left ventricular
dysfunction
270
![Page 271: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/271.jpg)
Kawasaki Disease
Primarily affects children
~25% have coronary artery
abnormalities, usually several
weeks after symptom onset
Usually reversible: may cause
aneurysm formation or 2o
thrombosis and acute MI
Myocarditis / pericarditis also seen
271
![Page 272: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/272.jpg)
Brugada Syndrome
Unpredictable ventricular
dysrhythmias and syncope or
sudden cardiac death
More in < 50 years old
Inherited disorder of Na+ channels
Men > women
Most common in Asian patients
272
![Page 273: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/273.jpg)
Brugada Syndrome
No structural heart disease
Consider in children, teenagers,
young adults with unexplained
syncope or symptomatic
palpitations
ECG pattern: ST with “saddle-
back” or coved appearance V1-V3
RBBB often coexists
273
![Page 274: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/274.jpg)
Brugada Syndrome
274 Source Undetermined
![Page 275: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/275.jpg)
Brugada Syndrome
Untreated: 10% mortality / year
Only proven therapy: implantable
cardioverter – defibrillator (ICD)
Quinidine is proposed alternative in
settings where ICD’s are
unavailable or inappropriate (eg:
neonates)
275
![Page 276: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/276.jpg)
3.5.8 Ventricular
Aneurysm
276
![Page 277: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/277.jpg)
Ventricular Aneurysm
Persistent ST elevation following
acute myocardial infarction
Some ST elevation remains in 60%
of patients with anterior STEMI and
5% with inferior STEMI
Associated with paradoxical
movement of ventricular wall on
echocardiography
277
![Page 278: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/278.jpg)
Ventricular Aneurysm
ST elevation >2 weeks after AMI
Most common: precordial leads.
May be concave or convex
Usually associated with well-
formed Q- or QS waves.
Relatively small T-waves
Unlike hyperacute T-waves of AMI
278
![Page 279: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/279.jpg)
Ventricular Aneurysm
279
Source Undetermined
![Page 280: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/280.jpg)
Predispose To
Ventricular arrhythmias and sudden
cardiac death
Myocardial scar tissue is
arrhythmogenic
Congestive cardiac failure
Mural thrombus and embolization
Myocardial rupture and death
280
![Page 281: GEMC- Cardiovascular Board Review Session 2- Resident Training](https://reader035.fdocuments.in/reader035/viewer/2022062513/555bd862d8b42ae4478b54ab/html5/thumbnails/281.jpg)
281